Health Care Distributors

Realcan

Realcan released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 1.707 B, actual EPS CNY 0.0069

Realcan released FY2025 Annual Earnings on April 22 After-Market (BJT), actual revenue CNY 7.296 B, actual EPS CNY 0.01

Realcan released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 1.889 B, actual EPS CNY 0.002

Realcan to Release FY2026 Q1 Earnings on April 27 After-Market BJT

Realcan to Release FY2025 Earnings on April 23, 2026, After-Market BJT

Realcan released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 1.863 B, actual EPS CNY -0.004

Realcan released FY2025 9 Months Earnings on October 29 After-Market (BJT), Actual Revenue: CNY 5.407B, Actual EPS: CNY 0.0066

Realcan FY2025 Q3 Earnings Release on October 30 After-Market BJT

Realcan released FY2025 Semi-Annual Earnings on August 25 During-Market (BJT), Actual Revenue CNY 3.544 B, Actual EPS CNY 0.0107

Realcan released FY2025 Q2 earnings on August 25 During-Market (BJT), actual revenue CNY 1.787 B, actual EPS CNY 0.0026

Realcan released FY2024 Semi-Annual earnings on August 25 Pre-Market (BJT), actual revenue CNY 4.032 B, actual EPS CNY 0.0178

Realcan FY2025 Semi-Annual Earnings Release on August 26, 2025 (BJT)

Ruikang Medicine repurchased 20.4465 million shares

Ruikang Pharmaceutical Director Placed Under Custody, Shares Open Lower

Rikang Medicine Shareholder Sells Shares

Major shareholder of Ruikang Medicine plans to reduce holdings

Realcan released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 1.757 B, actual EPS CNY 0.008

Ruikang Pharmaceutical Announces 2024 Financial Report, Net Profit Up 1.50%

Realcan released FY2024 earnings on April 23 After-Market (BJT), actual revenue CNY 7.967 B, actual EPS CNY 0.01

Realcan released FY2024 Q4 earnings on April 23 After-Market BJT, actual revenue CNY 1.91 B, actual EPS CNY -0.0516

02513

002793

002589

In the morning session, the CPO concept strengthened again, with DSBJ hitting the daily limit, EverProX rising over 5% to continue setting new record highs, and LINKTEL TECHNOLOGIES, Huamao Technology, TACLINK, and CIG following the gains. Innovative drug stocks were active against the trend in the morning, with YIBAI PHARMACEUTICAL achieving three daily limits in six days, Menovo hitting the daily limit, and Jincheng Pharm, JINLING PHARM., Luoxin Pharmaceutical, and Realcan following the upward trend

Wallstreetcn

KNOWLEDGE ATLAS

Luoxin Pharmaceutical

DSBJ

EverProX

JINLING PHARM.

TACLINK

Jincheng Pharm

Menovo

LINKTEL TECHNOLOGIES

YIBAI PHARMACEUTICAL

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

Tianhong CSI Computer Theme ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

Guotai CSI Computer Theme ETF

China Southern CSI Semiconductor Industry Custom ETF

Guotai CES Semiconductor Chip Industry ETF

ChinaAMC Guozheng Semiconductor Chip ETF

A-share Three Major Indices Fell Collectively, Computing Hardware Active Against the Trend, Hang Seng Tech Index Down Over 1%, AI Large Model Stocks Rebound, KNOWLEDGE ATLAS Rises 7%

600829

600272

000411

000078

Pharmaceutical commercial stocks are repeatedly active, NEPTUNUS has a 6-day consecutive limit-up, Realcan hits the limit-up, HRPC, SHKK, INT'L GROUP, and others follow suit. In news, China's drug price registration system has officially launched

HRPC

SHKK

INT'L GROUP

NEPTUNUS

Realcan announced that its revenue for the third quarter was 1.863 billion yuan, a year-on-year decrease of 7.98%; the net profit loss was 6.0298 million yuan. Revenue for the first three quarters was 5.407 billion yuan, a year-on-year decrease of 10.73%; the net profit was 12.1366 million yuan, a year-on-year decrease of 63.05%

Zhitong

Realcan: Net profit loss of 6.0298 million yuan in the third quarter

Realcan announced that on August 12, 2025, the company received a "Notice of Change of Detention" issued by the Supervisory Committee of Jiyang District, Jinan City, stating that the detention measures against Li Zhe have been lifted and changed to a directive for pending investigation. Currently, the company's production and operation are normal, and Li Zhe is able to perform his duties normally

Realcan: The company's director, board secretary, and vice president Li Zhe has been released from detention and changed to a directive for further investigation

On July 13th, Realcan announced that the company's director and vice president, Han Chunlin, applied to resign from his positions as director and vice president of the company, as well as from all other positions in the company and its subsidiaries, due to personal reasons. After his resignation, he will no longer hold any positions in the company or its holding subsidiaries. Han Chunlin's resignation report will take effect from the date it is delivered to the company's board of directors. As of the date of this announcement, Mr. Han Chunlin does not hold any company stock and there are no unfulfilled commitments

Realcan: Han Chunlin resigns as director and vice president

The board secretary of Realcan, Li Zhe, has been subjected to detention measures, resulting in a 1.33% drop in the company's stock price, which is reported at 2.97 yuan per share. The company responded that this matter is unrelated to its business, and the board and management are operating normally, with no significant impact on production and operations

Realcan's Secretary of the Board has been placed under residential surveillance; previously served as an investment banking project manager. The company responds

Realcan announced that director, board secretary, and vice president Li Zhe is unable to perform his duties due to being subjected to detention measures by the Jiyang District Supervisory Committee of Jinan City. To ensure the normal operation of the company, securities affairs representative Wang Xiuting will perform his duties. The company's governance structure is sound, and other management personnel are performing their duties normally, with no significant impact on production and operations

Realcan's director, board secretary, and vice president Li Zhe has been subjected to detention measures

The share transfer agreement signed by Ms. Zhang Renhua, the controlling shareholder of Realcan, and Yanquan No. 8 Fund has been terminated due to changes in the objective environment. Ms. Zhang Renhua originally planned to transfer 76 million shares of the company (accounting for 5.05% of the total share capital), and has now reached a friendly negotiation to terminate the agreement and signed a supplementary agreement

Realcan's controlling shareholder terminates the agreement to transfer part of the company's shares

According to the Zhitong Finance APP, Realcan announced that its shareholder Jingzhou Zhaoshang Huize Pharmaceutical Investment Partnership (Limited Partnership) plans to reduce its holdings in the company by no more than 15.0471 million shares through centralized bidding or block trading, which is no more than 1% of the company's total share capital

Realcan's shareholder Jingzhou Huize plans to reduce its holdings by no more than 1%

603883

600713

301017

603716

The pharmaceutical commercial sector fluctuated and rose sharply, LBX hit the daily limit, Realcan rose over 5%, Thalys, NPC, and SYPM followed suit

NPGC

SYPM

Thalys

The pharmaceutical commercial sector fluctuated and surged, LBX hit the limit up

Realcan(002589.SZ)